ArrowMark Colorado Holdings’s Zenas BioPharma ZBIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$14.6M Sell
573,318
-85,591
-13% -$1.7M 0.61% 39
2026
Q1
$12.9M Sell
658,909
-92,252
-12% -$2.07M 0.34% 87
2025
Q4
$27.3M Sell
751,161
-73,507
-9% -$2.42M 0.6% 50
2025
Q3
$18.3M Sell
824,668
-269,670
-25% -$4.39M 0.34% 82
2025
Q2
$10.6M Sell
1,094,338
-3,031
-0.3% -$29.5K 0.19% 122
2025
Q1
$8.67M Buy
1,097,369
+469,700
+75% +$3.68M 0.14% 136
2024
Q4
$5.14M Buy
627,669
+327,669
+109% +$5.11M 0.07% 190
2024
Q3
$5.08M Buy
+300,000
New +$5.39M 0.07% 188

Other funds holding ZBIO

ArrowMark Colorado Holdings's ZBIO Position: Q2 2026 in Review

ArrowMark Colorado Holdings reduced its Zenas BioPharma (ZBIO) stake by 13% in Q2 2026, selling an estimated $1.7M and leaving 573,318 shares worth $14.6M. The position accounts for 0.61% of the portfolio, ranked #39.

ArrowMark Colorado Holdings first reported a position in ZBIO in Q3 2024 and has held it in 8 quarters since. The position peaked at $27.3M in Q4 2025. 144 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • ArrowMark Colorado Holdings held 573,318 shares of Zenas BioPharma worth $14.6M as of Q2 2026.
  • ArrowMark Colorado Holdings sold 85,591 Zenas BioPharma shares in Q2 2026, an estimated $1.7M.
  • Zenas BioPharma made up 0.61% of ArrowMark Colorado Holdings's portfolio in Q2 2026, its #39 holding.
  • ArrowMark Colorado Holdings first reported a position in Zenas BioPharma in Q3 2024 and has held it in 8 quarters since.
  • ArrowMark Colorado Holdings's Zenas BioPharma position peaked at $27.3M in Q4 2025.
  • 144 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on ArrowMark Colorado Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.